Bayer shares dented by pessimistic profit outlook

28 February 2023

Werner Baumann, chairman of the board of management at the German life sciences major Bayer (BAYN: DE), presented his final set of annual financial results on Tuesday.

While the overall 2022 results were positive and met the company’s guidance, the year’s final quarter underwhelmed and Bayer’s expectations for 2023 have concerned investors, leading to a 3% drop in the firm’s share price on Tuesday.

Bayer’s sales for 2022 came it at 50.74 billion euros ($54 billion), a 15% rise on 2021, while earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for special items, were 13.51 billion euros, up 21%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK